Howard Colman is a Neurology physician affiliated with University of Utah. OpenAlex indexes 409 publications with 44,819 citations (h-index 71); ClinicalTrials.gov lists 4 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Neurology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2000 Circle Of Hope Dr
Dept. Of Neurosurgery And Huntsman Cancer Institute
Salt Lake City, UT 841125550
Telephone
801-587-4024Provider last certified this registry record 12 Nov 2021.
Clinical trials
- Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Sponsor: Orbus Therapeutics, Inc.
- Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors
Sponsor: University of California, San Francisco
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Bayer Healthcare Pharmaceuticals Inc.Program year20251 payment
- SERVIER PHARMACEUTICALS LLCProgram year20251 payment
- SERVIER PHARMACEUTICALS LLCProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
54.2%Serotonin-3 Receptor Antagonist54.2%Ondansetron Hcl100%Part D≥11 patientsCancer & immunology
45.8%Isocitrate Dehydrogenase 1 Inhibitor45.8%Tibsovo100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2026–2026 per NIH RePORTER. The latest:
- Effects of combined FAK inhibition with MAPK blockade in brain metastases from cutaneous melanoma
Utah State Higher Education System--University of Utah
FY2026$634,900R01CA300362 - Protocol Review and Monitoring System
Utah State Higher Education System--University of Utah
FY2026$269,453P30CA042014
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A first-in-human phase 0 clinical study of RNA interference–based spherical nucleic acids in patients with recurrent glioblastoma
Science Translational Medicine
2021 - cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas
Acta Neuropathologica
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Varner, MD
University of Utah
James Fang
University of Utah
Wallace Akerley, MD
University of Utah
Randall Burt, MD
University of Utah
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”